Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryBaylor Scott & White Luxturna Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentBaylor Scott & White Health PlanPolicy 249

    Voretigene neparvovec-rzyl (Luxturna) for RPE65-associated retinal dystrophy

    Customize your policy alerts

    Sign up for Baylor Scott & White Health Plan Policy 249 alerts

    Get alerted when Policy 249 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and prior authorization for voretigene neparvovec-rzyl (Luxturna) for members with confirmed biallelic RPE65 mutation-associated retinal dystrophy. It applies across lines of business unless otherwise specified, subject to the member’s benefit plan, applicable Medicare or Medicaid requirements, and federal or state mandates.

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyVoretigene neparvovec-rzyl (Luxturna) for RPE65-associated retinal dystrophy
    Policy CodePolicy 249
    Change TypeMinor formatting update
    Effective DateSep 1, 2026
    Last ReviewAug 27, 2026
    Next Review DateAug 27, 2027
    Key ActionPrior authorization is required; submit clinical documentation supporting all policy criteria before treatment.
    SourceLink
    POLICY UPDATE CHANGES

    The 2026-08-27 policy history identifies minor formatting changes as the latest update.

    RequiredPrior authorization
    10Covered-treatment criteria
    12 mo–65 yrMember age range
    1/eye/lifetime

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Lifetime treatment limit
    6 daysSecond-eye interval
    J3398HCPCS drug code

    Luxturna Coverage Criteria

    Initial Luxturna treatment

    Covered when ALL of the following are met and supporting documentation is submitted:

    Diagnosis and eligibility: The member has confirmed biallelic RPE65 mutation-associated retinal dystrophy (for example, Leber congenital amaurosis, retinitis pigmentosa, or early-onset severe retinal dystrophy); is between 12 months and 65 years of age; and genetic testing results confirm biallelic RPE65 mutations.Age: 12 months through 65 years
    Provider and administration: Voretigene neparvovec-rzyl is prescribed and administered by an ophthalmologist or retinal surgeon with experience providing sub-retinal injections; dosing and administration follow FDA-approved labeling; the provider attests that the member will use a designated treatment center; the member has not previously received RPE65 gene therapy in the intended eye; and injection of the second eye occurs at least 6 days after injection of the first eye.Second-eye interval: at least 6 days

    Sufficient viable retinal cells

    • Optical coherence testing: An area of retina within the posterior pole has thickness greater than 100 um on optical coherence testing.>100 um
    • Retina without degeneration: There are at least 3 disc areas of retina without atrophy or pigmentary degeneration within the posterior pole.>=3 disc areas within the posterior pole
    • Remaining visual field is within 30 degrees of fixation in both eyes, measured by a III4e isopter or equivalent.Within 30 degrees of fixation in both eyes
    Surgical history: The member has had no intraocular surgery within 6 months in either eye that was indicated for treatment.No qualifying surgery within 6 months

    Lifetime treatment limitation

    The following treatment limitation applies:

    Treatment limitation: Only one treatment per eye per lifetime is medically necessary. Repeat administration of voretigene neparvovec in the same eye is considered experimental and investigational because the effectiveness of this strategy has not been established.1 treatment per eye per lifetime

    Repeat administration of voretigene neparvovec-rzyl (Luxturna) in the same eye is considered experimental and investigational. The policy considers only one treatment per eye per lifetime medically necessary because the effectiveness of repeat administration has not been established.

    Voretigene neparvovec-rzyl for indications other than confirmed biallelic RPE65 mutation-associated retinal dystrophy is considered experimental and investigational because the effectiveness of treatment for other indications has not been established.

    Coding and Clinical Thresholds

    HCPCS CodesHCPCS
    J3398Injection, voretigene neparvovec-rzyl, 1 billion vector genomes
    ICD10 codesICD-10
    H35.50Unspecified hereditary retinal dystrophy
    Member age
    Eligible age range12 months through 65 years
    Policy applicationThe member must be within this age range for covered treatment.
    Eligibility contextTreatment is for confirmed biallelic RPE65 mutation-associated retinal dystrophy.
    Posterior-pole retinal thickness
    Minimum thickness>100 um
    Retinal locationThe qualifying area must be within the posterior pole.
    Measurement method

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Submit the request with clinical documentation supporting medical necessity and all applicable coverage criteria for voretigene neparvovec-rzyl (Luxturna®).

    • Include the member’s diagnosis, genetic testing, retinal-cell viability, surgical history, prescribing and administration details, and treatment-center documentation.
    Note

    Two-Level Clinical Review

    All requests are reviewed at two clinical levels: by a clinical pharmacist and a medical director.

    Documentation Required

    Diagnosis and Genetic Testing

    Clinical Background

    Luxturna is an adeno-associated virus 2 gene therapy containing functional human RPE65 complementary DNA. It is indicated for confirmed biallelic RPE65 mutation-associated retinal dystrophy. The policy notes limited evidence, including a single published phase III trial, and reports that visual-acuity improvement was not statistically significant in the intention-to-treat population.

    Key Definitions

    Inherited retinal disease (IRD)
    DefinitionInherited retinal diseases are a group of eye disorders caused by inherited gene mutations.
    RPE65 relationshipThe group includes disorders caused by RPE65 mutations.
    Potential effectThese disorders can result in vision loss or blindness.
    Retinal pigment epithelium (RPE)
    DefinitionThe retinal pigment epithelium is a thin layer of cells at the back of the eye.
    RPE65 gene roleThe RPE65 gene provides instructions for making a protein essential for normal vision produced in the RPE.
    Effect of mutation
    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyVoretigene neparvovec-rzyl (Luxturna) for RPE65-associated retinal dystrophy
    Policy CodePolicy 249
    Change TypeMinor formatting update
    Effective DateSep 1, 2026
    Last ReviewAug 27, 2026
    Next Review DateAug 27, 2027
    Key ActionPrior authorization is required; submit clinical documentation supporting all policy criteria before treatment.
    SourceLink
    On This Page
    Luxturna Coverage CriteriaCoding and Clinical ThresholdsAuthorization and Documentation RequirementsClinical BackgroundKey Definitions
    Thickness must be shown on optical coherence testing.
    Retina without atrophy or pigmentary degeneration
    Minimum retinal areaGreater than or equal to 3 disc areas
    Retinal conditionThe retina must be without atrophy or pigmentary degeneration.
    Retinal locationThe qualifying area must be within the posterior pole.
    Remaining visual field
    Required visual fieldWithin 30 degrees of fixation in both eyes
    Measurement methodMeasured by a III4e isopter or equivalent.
    Eligibility roleThis is one accepted measure of sufficient viable retinal cells.
    Intraocular surgery exclusion period
    Required surgical historyNo qualifying intraocular surgery within the preceding 6 months
    Eyes includedThe requirement applies to either eye.
    Surgery qualificationThe surgery must have been indicated for treatment.
    Second-eye injection interval
    Minimum intervalAt least 6 days after injection of the first eye
    Applies toInjection of the second eye.
    Administration requirementDosing and administration must follow FDA-approved labeling.
    Lifetime treatment limit
    Lifetime limitOne treatment per eye per lifetime
    Repeat treatment statusRepeat administration in the same eye is experimental and investigational.
    Medical-necessity rationaleThe effectiveness of repeat administration has not been established.

    Document a confirmed biallelic RPE65 mutation-associated retinal dystrophy and provide genetic test results confirming biallelic RPE65 gene mutations.

    • Examples include Leber’s congenital amaurosis (LCA), retinitis pigmentosa (RP), and early-onset severe retinal dystrophy (EOSRD).
    • Document that the member is between 12 months and 65 years of age.
    Documentation Required

    Viable Retinal-Cell Documentation

    Document sufficient viable retinal cells as determined by the treating physician(s), using at least one accepted measure.

    • An area of retina within the posterior pole of >100 µm thickness shown on optical coherence testing.
    • ≥3 disc areas of retina without atrophy or pigmentary degeneration within the posterior pole.
    • Remaining visual field within 30 degrees of fixation as measured by a III4e isopter or equivalent in both eyes.
    Documentation Required

    Recent Intraocular Surgery History

    Document that the member has had no intraocular surgery within the preceding six months in either eye when the surgery was indicated for treatment.

    Documentation Required

    Provider, Treatment Center, and Administration Attestation

    The prescribing and administering ophthalmologist or retinal surgeon must have experience providing sub-retinal injections. The provider must attest that treatment will occur at a designated treatment center and that administration will comply with FDA-approved labeling.

    • Document the prescribed and administered dose and schedule according to FDA-approved labeling.
    • Attest that the member will use a designated treatment center.
    • Document that the member has not previously received RPE65 gene therapy in the intended eye.
    • For bilateral treatment, administer injection in the second eye at least 6 days after injection in the first eye.
    Denial Risk

    Failure to Meet Covered-Treatment Criteria

    Coverage requires documentation that all applicable criteria are met. Failure to meet any required criterion—including age, diagnosis, genetic confirmation, viable retinal cells, surgical-history, provider, treatment-center, dosing, prior-treatment, or injection-timing requirements—may result in denial.

    • Voretigene neparvovec-rzyl must be prescribed and administered by an appropriately experienced ophthalmologist or retinal surgeon.
    • The member must be 12 months through 65 years of age and must meet the required treatment and administration conditions.
    Denial Risk

    Repeat Treatment in an Eye

    Only one treatment per eye per lifetime is medically necessary. Repeat administration of voretigene neparvovec in the same eye is considered experimental and investigational because effectiveness has not been established.

    • The member must not have previously received RPE65 gene therapy in the intended eye.
    Denial Risk

    Other Indications

    Voretigene neparvovec-rzyl for indications other than confirmed biallelic RPE65 mutation-associated retinal dystrophy is considered experimental and investigational because effectiveness has not been established.

    RPE65 mutations lead to partial or total loss of RPE65 protein function.
    Voretigene neparvovec-rzyl (Luxturna)
    ProductVoretigene neparvovec-rzyl (Luxturna) is a gene therapy indicated for confirmed biallelic RPE65 mutation-associated retinal dystrophy.
    VectorIt uses an adeno-associated virus 2 (AAV2) vector.
    MechanismThe vector contains human RPE65 complementary DNA (cDNA), which is inserted as a functional gene into a cell.